查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
数位生物标记市场 - 按产品类型、按解决方案目的、按生物标记类型、按治疗领域、按商业模式、按关键地区：行业趋势和全球预测
市场调查报告书
商品编码
1471915

数位生物标记市场 - 按产品类型、按解决方案目的、按生物标记类型、按治疗领域、按商业模式、按关键地区：行业趋势和全球预测

Digital Biomarkers Market - Distribution by Type of Product, Purpose of Solution, Type of Biomarker, Therapeutic Area, Business Model and Key Geographical Regions : Industry Trends and Global Forecasts
出版日期: | 出版商: Roots Analysis | 英文 369 Pages | 商品交期: 最快1-2个工作天内

价格

到 2024 年，数位生物标记市场规模预计将达到 55.5 亿美元，2024-2035 年预测期间复合年增长率为 18.5%。

手动追踪个人健康资料的传统方法包括评估关键健康资讯的延迟、容易出错、耗时且成本高昂的过程以及健康记录遗失或损坏的风险。 这些因素阻碍了及时治疗，尤其是在人口老化的情况下。 令人担忧的是，据估计，65% 的医院患者和超过 90% 的急性后护理患者每 4 至 8 小时接受一次生命体征和患者特定参数的手动监测。 因此，远距医疗成为人们关注的焦点，利用数位工具提供远距咨询和服务。 值得注意的是，数位医疗技术实现了持续的患者监测，使医护人员能够快速追踪个别患者的基线变化。

此外，事实证明，实施连续监测系统可以显着减少不良事件和再入院率。 快速发展的数位生物标记和数位疗法领域是更广泛的数位健康市场的重要组成部分。 此外，根据世界卫生组织（WHO）的预测，到2030年，全球六分之一的人口将超过60岁。 因此，在早期阶段主动检测症状直观上比等待更长时间并治疗病情较重的患者更好。 研究表明，持续症状追踪和早期介入不仅可以显着改善患者的生活质量，还可以降低医疗成本。

医疗保健产业日益数位化促进了多种数位解决方案的开发，这些解决方案可以透过体内的生物标记物产生、收集和追踪医疗资讯。 生物标记的数位解决方案包括智慧型手机、感测器和穿戴式设备，用于测量血压、情绪健康、心率、血糖水平、身体活动、呼吸功能和睡眠模式等生理、行为和生物特征数据——定义为数字。 这些先进的解决方案可以即时监测个人的健康状况，鼓励积极参与健康活动，并根据个人数据量身定制治疗方案，特别是在慢性病管理方面。 慢性病盛行率的上升、对远端患者监测的日益重视以及技术的持续进步可能会在短期内推动数位生物标记市场的成长。

本报告调查了全球数位生物标记市场，并提供了市场概述，以及按产品类型、解决方案目的、生物标誌物类型、治疗领域、商业模式、地区和市场划分的趋势及公司的概况。

目录

第1章前言

第2章研究方法

第 3 章经济与其他专案特定考量

第 4 章执行摘要

第 5 章简介

第6章市场状况

  • 章节概述
  • 数位生物标记解决方案：市场情势
  • 数位生物标记解决方案：开发者格局

第7章产品竞争力分析

  • 章节概述
  • 假设和主要参数
  • 调查方法
  • 数位生物标记解决方案：产品竞争分析

第 8 章公司简介：数位生物标记解决方案开发公司

第 9 章伙伴关係与协作

  • 章节概述
  • 合作伙伴模式
  • 数位生物标记解决方案：伙伴关係与协作

第10章融资与投资

  • 章节概述
  • 融资模式
  • 数位生物标记解决方案：融资和投资

第11章世界事件分析

第12章专利分析

第13章主要药厂的举措

第 14 章市场影响分析：驱动因素、限制因素、机会、挑战

  • 章节概述
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场挑战
  • 结论

第 15 章全球数位生物标记解决方案市场

第 16 章数位生物标记解决方案市场（按产品类型）

第 17 章数位生物标记解决方案市场（按解决方案目的）

第 18 章数位生物标记解决方案市场（按生物标记类型）

第 19 章数位生物标记解决方案市场（按治疗领域）

第 20 章数位生物标记解决方案市场（按业务模式）

第 21 章数位生物标记解决方案市场（按主要地区）

第22章结论

第 23 章高阶主管洞察力

第 24 章附录 1：表格资料

第 25 章附录 2：公司与组织名单

Product Code: RA100488

The digital biomarkers market is valued at USD 5.55 billion in 2024 growing at a CAGR of 18.5% during the forecast period 2024-2035.

The conventional approach of manually tracking individuals' health data is fraught with numerous challenges, including delays in assessing critical health information, susceptibility to errors, time-consuming and costly processes, and the risk of loss or damage to health records. These factors hinder timely treatment, particularly for the aging population. Alarmingly, it is estimated that 65% of hospital patients and more than 90% of post-acute care patients undergo manual monitoring of vitals and patient-specific parameters every four to eight hours. As a result, telemedicine has gained prominence, leveraging digital tools to provide remote consultations and services. Notably, digital health technologies enable continuous patient monitoring, allowing healthcare practitioners to promptly track baseline changes in individual patients. Additionally, the implementation of continuous monitoring systems has proven to significantly reduce adverse events and hospital readmissions. The burgeoning fields of digital biomarkers and digital therapeutics are integral components of the broader digital health market. Furthermore, according to the World Health Organization, by 2030, one-sixth of the global population will be aged over 60 years. Consequently, proactively detecting symptoms at an early stage is intuitively better than treating patients who are seriously ill due to longer waiting times. Studies have demonstrated that continuous symptom tracking with early intervention has not only led to remarkable improvements in patients' quality of life but has also reduced healthcare costs.

The rising digitalization in the healthcare industry has catalyzed the development of several digital solutions capable of generating, collecting, and tracking medical information via biomarkers in the body. Digital solutions for biomarkers are defined as digital devices, such as smartphones, sensors, and wearable devices, that measure and quantify physiological, behavioral, or biometric data, including blood pressure, emotional health, heart rate, glucose levels, physical activity, respiratory function, and sleep patterns. These advanced solutions enable real-time monitoring of an individual's health, specifically in chronic disease management, encourage proactive participation in wellness activities, and allow personalized healthcare by tailoring treatments based on individual data. With the rising prevalence of chronic diseases, growing emphasis on remote patient monitoring, and continuous advancements in technologies, the digital biomarkers market is poised for growth in the foreseeable future.

Key Market Segments

Type of Product

  • Software / Applications
  • Wearables
  • Sensors
  • Gaming Solutions

Purpose of Solution

  • Diagnosis
  • Early Detection
  • Monitoring
  • Predictive Insights

Type of Biomarker

  • Cognitive Biomarkers
  • Idiosyncratic Biomarkers
  • Physiological Biomarkers
  • Vocal Biomarkers
  • Other Biomarkers

Therapeutic Area

  • Autoimmune Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Mental Health Disorders
  • Neurological Disorders
  • Respiratory Disorders
  • Substance Abuse Disorders
  • Others

Business Model

B2B

B2C

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa (MENA)
  • Rest of the World

Research Coverage:

  • The report studies the digital biomarkers market based on type of product, purpose of solution, type of biomarker, therapeutic area, business model, and key geographical regions
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to five major regions
  • The report begins with a general overview of various solutions enabling digital monitoring / detection of biomarkers. It provides information on different types of digital biomarkers, biological signals captured by them, key advantages driving their growing adoption, existing concerns around reliability/credibility of analyzed health data and lack of guidelines. It also outlines the product development and commercialization path for digital biomarkers and highlights recent advances and prevalent trends in this field.
  • It offers a detailed assessment of the current digital biomarker solutions market landscape based on parameters like product type (software/apps, wearables, others), solution type (data collection, data integration), biomarker type (behavioral, cognitive, idiosyncratic, physiological, vocal, others), development status (approved, FDA registered, marketed, R&D), purpose (diagnosis, disease risk management, early detection, monitoring, prognosis, treatment), therapeutic area, target population, end-user type, clinical validation status, and AI integration. It also analyzes digital biomarker developers by year of establishment, company size, headquarters location, business model, and active players.
  • The report provides an insightful analysis of digital biomarker solutions based on developer strength (experience, size, model, number of solutions), product competitiveness (solution type, biomarker type, purpose, clinical validation, AI integration), and development status.
  • It includes elaborate profiles of key digital biomarker developers, featuring company overviews, biomarker portfolios, recent developments, and future outlooks.
  • The report presents a detailed analysis of partnerships between stakeholders from pre-2019 to 2024, based on year, partnership type, biomarker type, therapeutic area, partner type, active players, and regional distribution.
  • It features an analysis of funding/investments raised by digital biomarker developers based on year, funding type, amount, biomarker type, therapeutic area, active players/investors, and regional distribution.
  • The report analyzes global events attended by companies in this industry, based on year, event type, platform, organizer, location, active players, speakers, and designations.
  • It provides an in-depth analysis of digital biomarker patents filed/granted since 2019, based on patent type, publication/application year, jurisdiction, CPC symbols, applicant type, active players, benchmarking, and a patent valuation analysis highlighting leading patents by citations.
  • The report analyzes initiatives by big pharma players related to digital biomarkers, based on parameters like number of clinical trials, collaborations, conferences attended, funding instances, and publications.
  • It identifies and analyzes key drivers, restraints, opportunities, and challenges impacting the growth of the digital biomarkers market.
  • The report provides a detailed market forecast analysis to estimate the existing market size and future opportunity till 2035, based on likely adoption trends and primary validations. It includes three forecast scenarios (conservative, base, optimistic) to account for future uncertainties.
  • It offers detailed projections of the current and future market opportunity across product types (software / apps, wearables, sensors, gaming solutions), solution purposes (diagnosis, early detection, monitoring, predictive insights), biomarker types (cognitive, idiosyncratic, physiological, vocal, others), therapeutic areas, business models (B2B, B2C), and key geographical regions.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the digital biomarkers market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

  • Acculi Labs
  • ActiGraph
  • AliveCor

ATCOR

  • BACtrack
  • Biogen
  • BioSerenity
  • BioSensics
  • Eyenuk
  • Empatica
  • Feel Therapeutics
  • icometrix
  • iMediSync

IXICO

  • Kinsa
  • Koneksa Health
  • Kontigo Care
  • Progentec Diagnostics
  • Quibim
  • Vocalis Health

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Digital Biomarker Solutions Market
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCHMETHODOLOGY

  • 2.1 Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentation
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1 Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future Estimates
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
      • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1 Chapter Overview
  • 5.2. Overview of Digital Biomarkers
    • 5.2.1. Classification of Digital Biomarkers
    • 5.2.2. Types of Biological Signals Captured by Digital Biomarker Solutions
    • 5.2.3. Key Advantages and Limitations
  • 5.3. Product Development and Commercialization Path for Digital Biomarker Solutions
    • 5.3.1. Discovery
    • 5.3.2. Validations and Submissions
    • 5.3.3. Distribution and Marketing
  • 5.4. Recent Advancements related to Digital Biomarker Solutions
  • 5.5. Impact of COVID-19 Pandemic on the Digital Biomarkers Domain
  • 5.6. Prevalent Trends Related to Digital Biomarker Solutions
    • 5.6.1. Emerging Focus Areas

6. MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Digital Biomarker Solutions: Overall Market Landscape
    • 6.2.1. Analysis by Type of Product
    • 6.2.2. Analysis by Type of Digital Biomarker Solution
    • 6.2.3. Analysis by Type of Biomarker
    • 6.2.4. Analysis by Status of Development
    • 6.2.5. Analysis by Type of Biomarker and Status of Development
    • 6.2.6. Analysis by Purpose of Digital Biomarker Solution
    • 6.2.7. Analysis by Target Therapeutic Area
    • 6.2.8. Analysis by Type of Biomarker and Target Therapeutic Area
    • 6.2.9. Analysis by Target Population
    • 6.2.10. Analysis by End-user
    • 6.2.11. Analysis by Availability of Clinical Validation
    • 6.2.12. Analysis by Availability of Clinical Validates Solutions by Target Therapeutic Area
    • 6.2.13. Analysis by Availability of AI Integration
  • 6.3. Digital Biomarker Solutions: Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3 Analysis by Location of Headquarters
    • 6.3.4. Analysis by Company Size and Location of Headquarters
    • 6.3.5. Most Active Players: Analysis by Number of Digital Biomarker Solutions Developed

7. PRODUCT COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Assumptions and Key Parameters
  • 7.3. Methodology
  • 7.4. Digital Biomarker Solutions: Product Competitiveness Analysis
    • 7.4.1. Digital Biomarker Solutions Developed by Players based in North America
    • 7.4.2. Digital Biomarker Solutions Developed by Players based in Europe
    • 7.4.3. Digital Biomarker Solutions Developed by Players based in Asia-Pacific and Rest of the World

8. COMPANY PROFILES: DIGITAL BIOMARKER SOLUTIONS DEVELOPERS

  • 8.1. Chapter Overview
  • 8.2. Detailed Company Profiles of Leading Digital Biomarker Solutions Developers
    • 8.2.1. BioSensics
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Digital Biomarker Solutions Portfolio
      • 8.2.1.3. Recent Developments and Future Outlook
    • 8.2.2. AliveCor
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Digital Biomarker Solutions Portfolio
      • 8.2.2.3. Recent Developments and Future Outlook
    • 8.2.3. BACtrack
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Digital Biomarker Solutions Portfolio
      • 8.2.3.3. Recent Developments and Future Outlook
    • 8.2.4. Eyenuk
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Digital Biomarker Solutions Portfolio
      • 8.2.4.3. Recent Developments and Future Outlook
    • 8.2.5. Quibim
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Digital Biomarker Solutions Portfolio
      • 8.2.5.3. Recent Developments and Future Outlook
    • 8.2.6. Feel Therapeutics
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Digital Biomarker Solutions Portfolio
      • 8.2.6.3. Recent Developments and Future Outlook
    • 8.2.7. Empatica
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Digital Biomarker Solutions Portfolio
      • 8.2.7.3. Recent Developments and Future Outlook
    • 8.2.8. icometrix
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Digital Biomarker Solutions Portfolio
      • 8.2.8.3. Recent Developments and Future Outlook
    • 8.2.9. Biogen
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Digital Biomarker Solutions Portfolio
      • 8.2.9.3. Recent Developments and Future Outlook
  • 8.3. Short Company Profiles of Other Prominent Developers
    • 8.3.1. Acculi Labs
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.2. IXICO
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.3. Kinsa
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.4. Progentec Diagnostics
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.5. Vocalis Health
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.6. Kontigo Care
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.7. Koneksa Health
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.8. ActiGraph
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.9. BioSerenity
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.10. ATCOR
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Product Portfolio: Digital Biomarker Solutions
    • 8.3.11. iMediSync
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Product Portfolio: Digital Biomarker Solutions

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Digital Biomarker Solutions: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Biomarker
    • 9.3.5. Analysis by Type of Partnership and Type of Biomarker
    • 9.3.6 Analysis by Therapeutic Area
    • 9.3.7. Analysis of Type of Partnership and Therapeutic Area
    • 9.3.8. Analysis by Type of Partner
    • 9.3.9. Most Active Players: Analysis by Number of Partnerships
    • 9.3.10. Analysis by Geography
      • 9.3.10.1. Intracontinental and Intercontinental Deals
      • 9.3.10.2. International and Local Deals

10. FUNDING AND INVESTMENTS

  • 10.1. Chapter Overview
  • 10.2. Funding Models
  • 10.3. Digital Biomarker Solutions: Funding and Investments
    • 10.3.1. Analysis by Year of Investment
    • 10.3.2. Analysis by Amount Invested
    • 10.3.3. Analysis of Funding Instances by Type of Funding
    • 10.3.4. Analysis of Amount Invested by Type of Funding
    • 10.3.5. Analysis of Funding Instances by Type of Biomarker
    • 10.3.6. Analysis of Funding Instances and Amount Invested by Therapeutic Area
    • 10.3.7. Leading Investors: Distribution by Number of Funding Instances
    • 10.3.8. Most Active Players: Distribution by Number of Funding Instances
    • 10.3.9. Most Active Players: Analysis by Amount Raised
    • 10.3.10. Most Active Players: Analysis by Geography

11. GLOBAL EVENTS ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Digital Biomarker Solutions: Global Events Analysis
    • 11.3.1. Analysis by Year of Event
    • 11.3.2. Analysis by Type of Event
    • 11.3.3. Analysis by Year and Type of Event
    • 11.3.4. Analysis by Event Platform
    • 11.3.5. Analysis by Location of Event
    • 11.3.6. Word Cloud Analysis: Key Focus Areas
    • 11.3.7. Most Active Event Organizers: Analysis by Number of Events
    • 11.3.8. Most Active Players: Analysis by Number of Events
  • 11.4. Global Events: Speaker Analysis
    • 11.4.1. Most Active Speakers: Analysis by Number of Events
    • 11.4.2. Analysis by Designation / Qualification of Speakers
  • 11.5. List of Upcoming Global Events
  • 11.6. Concluding Remarks

12. PATENT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Digital Biomarker Solutions: Patent Analysis
    • 12.3.1. Analysis by Patent Application Year
    • 12.3.2. Analysis by Patent Publication Year
    • 12.3.3. Analysis by Type of Patent and Patent Publication Year
    • 12.3.4. Analysis by Patent Jurisdiction
    • 12.3.5. Analysis by CPC Symbols
    • 12.3.6. Analysis by Patent Publication Year and Type of Applicant
    • 12.3.7. Leading Players: Analysis by Number of Patents
    • 12.3.8. Leading Patent Assignees: Analysis by Number of Patents
  • 12.4. Patent Benchmarking Analysis
    • 12.4.1. Analysis By Patent Characteristics
  • 12.5. Patent Valuation
  • 12.6. Leading Patents by Number of Citations

13. BIG PHARMA INITIATIVES

  • 13.1. Chapter Overview
  • 13.2. Methodology and Key Parameters
  • 13.3. Big Pharma Initiatives Related to Digital Biomarker Solutions
    • 13.3.1. Analysis by Type of Initiatives
    • 13.3.2. Heat Map Analysis
  • 13.4. Big Pharma Players: Benchmark Analysis
    • 13.4.1. Spider Web Analysis: AbbVie
    • 13.4.2. Spider Web Analysis: Amgen
    • 13.4.3. Spider Web Analysis: AstraZeneca
    • 13.4.4. Spider Web Analysis: Bayer
    • 13.4.5. Spider Web Analysis: Bristol Myers Squibb
    • 13.4.6. Spider Web Analysis: Eli Lilly
    • 13.4.8. Spider Web Analysis: GlaxoSmithKline
    • 13.4.8. Spider Web Analysis: Johnson & Johnson
    • 13.4.9. Spider Web Analysis: Merck
    • 13.4.10. Spider Web Analysis: Novartis
    • 13.4.11. Spider Web Analysis: Pfizer
    • 13.4.12. Spider Web Analysis: Roche
    • 13.4.13. Spider Web Analysis: Sanofi
    • 13.4.14. Spider Web Analysis: Takeda Pharmaceuticals
  • 13.5. Most Active Players: Distribution by Number of Initiatives

14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 14.1. Chapter Overview
  • 14.2. Market Drivers
  • 14.3. Market Restraints
  • 14.4. Market Opportunities
  • 14.5. Market Challenges
  • 14.6. Conclusion

15. GLOBAL DIGITAL BIOMARKER SOLUTIONS MARKET

  • 15.1. Chapter Overview
  • 15.2. Assumptions and Methodology
  • 15.3. Global Digital Biomarker Solutions Market, Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 15.3.1. Scenario Analysis
      • 15.3.1.1. Conversative Scenario
      • 15.3.1.2. Optimistic Scenario
  • 15.4. Key Market Segmentation

16. DIGITAL BIOMARKER SOLUTIONS MARKET, BY TYPE OF PRODUCT

  • 16.1. Chapter Overview
  • 16.2. Assumptions and Methodology
  • 16.3. Digital Biomarker Solutions Market: Distribution by Type of Product, 2018, 2024 and 2035
    • 16.3.1. Digital Biomarker Solutions Market for Software / Applications: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 16.3.2. Digital Biomarker Solutions Market for Wearables: Historical Trends Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 16.3.3. Digital Biomarker Solutions Market for Sensors: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 16.3.4. Digital Biomarker Solutions Market for Gaming Solutions: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 16.4. Data Triangulation and Validation

17. DIGITAL BIOMARKER SOLUTIONS MARKET, BY PURPOSE OF SOLUTION

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Methodology
  • 17.3. Digital Biomarker Solutions Market: Distribution by Purpose of Solution, 2018, 2024 and 2035
    • 17.3.1. Digital Biomarker Solutions Market for Monitoring: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 17.3.2. Digital Biomarker Solutions Market for Diagnosis: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 17.3.3. Digital Biomarker Solutions Market for Early Detection: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 17.3.4. Digital Biomarker Solutions Market for Predictive Insights: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 17.4. Data Triangulation and Validation

18. DIGITAL BIOMARKER SOLUTIONS MARKET, BY TYPE OF BIOMARKER

  • 18.1. Chapter Overview
  • 18.2. Assumptions and Methodology
  • 18.3. Digital Biomarker Solutions Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
    • 18.3.1. Digital Biomarker Solutions Market for Physiological Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 18.3.2. Digital Biomarker Solutions Market for Vocal Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 18.3.3. Digital Biomarker Solutions Market for Cognitive Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 18.3.4. Digital Biomarker Solutions Market for Idiosyncratic Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 18.3.5. Digital Biomarker Solutions Market for Other Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 18.4. Data Triangulation and Validation

19. DIGITAL BIOMARKER SOLUTIONS MARKET, BY THERAPEUTIC AREA

  • 19.1. Chapter Overview
  • 19.2. Assumptions and Methodology
  • 19.3. Digital Biomarker Solutions Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
    • 19.3.1. Digital Biomarker Solutions Market for Neurological Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.2. Digital Biomarker Solutions Market for Mental Health Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.3. Digital Biomarker Solutions Market for Cardiovascular Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.4. Digital Biomarker Solutions Market for Infectious Diseases: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.5. Digital Biomarker Solutions Market for Respiratory Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.6. Digital Biomarker Solutions Market for Autoimmune Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.7. Digital Biomarker Solutions Market for Substance Abuse Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.8. Digital Biomarker Solutions Market for Other Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 19.4. Data Triangulation and Validation

20. DIGITAL BIOMARKER SOLUTIONS MARKET, BY BUSINESS MODEL

  • 20.1. Chapter Overview
  • 20.2. Assumptions and Methodology
  • 20.3. Digital Biomarker Solutions Market: Distribution by Business Model, 2018, 2024 and 2035
    • 20.3.1. Digital Biomarker Solutions Market for B2B Model: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 20.3.2. Digital Biomarker Solutions Market for B2C Model: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 20.4. Data Triangulation and Validation

21. DIGITAL BIOMARKER SOLUTIONS MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 21.1. Chapter Overview
  • 21.2. Assumptions and Methodology
  • 21.3. Digital Biomarker Solutions Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
    • 21.3.1. Digital Biomarker Solutions Market in North America: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 21.3.2. Digital Biomarker Solutions Market in Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 21.3.3. Digital Biomarker Solutions Market in Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 21.3.4. Digital Biomarker Solutions Market in Middle East and North Africa (MENA): Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 21.3.5. Digital Biomarker Solutions Market in Rest of the World: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 21.8. Data Triangulation and Validation

22. CONCLUDING REMARKS

23. EXECUTIVE INSIGHTS

  • 23.1. Chapter Overview
  • 23.2. Acculi Labs
    • 23.2.1. Company Snapshot
    • 23.2.2. Interview Transcript: Rupam Das, Chief Executive Officer
  • 23.3. IXICO
    • 23.3.1. Company Snapshot
    • 23.3.2. Interview Transcript: Rohan Sopp, Business Development Manager
  • 23.4. Tilak Healthcare
    • 23.4.1. Company Snapshot
    • 23.4.2. Interview Transcript: Edouard Gasser, Co-Founder and Chief Executive Officer
  • 23.5. Vocalis Health
    • 23.5.1. Company Snapshot
    • 23.5.2. Interview Transcript: Michael Seggev, Former Chief Commercial Officer

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List of Tables

  • Table 5.1 Key Advantages and Limitations for Digital Biomarkers
  • Table 6.1 Digital Biomarker Solutions: Overall Market Landscape
  • Table 6.2 Digital Biomarker Solutions: Information on Status of Development, Approving Authority, Launch Data and Purpose of Biomarker Solutions
  • Table 6.3 Digital Biomarker Solutions: Information on Target Indication, Target Therapeutic Area, Target Population and Target Segment
  • Table 6.4 Digital Biomarker Solutions: Information on Solution Specifications, End-user, Clinical Validation and AI Integration
  • Table 6.5 Digital Biomarker Solutions: Developers Landscape
  • Table 8.1 Players Developing Digital Biomarker Solutions: List of Companies Profiled
  • Table 8.2 BioSensics: Company Snapshot
  • Table 8.3 BioSensics: Digital Biomarker Solutions Portfolio
  • Table 8.4 BioSensics: Recent Developments and Future Outlook
  • Table 8.5 Eyenuk: Company Snapshot
  • Table 8.6 Eyenuk: Digital Biomarker Solutions Portfolio
  • Table 8.7 Eyenuk: Recent Developments and Future Outlook
  • Table 8.8 Quibim: Company Snapshot
  • Table 8.9 Quibim: Digital Biomarker Solutions Portfolio
  • Table 8.10 Quibim: Recent Developments and Future Outlook
  • Table 8.11 Feel Therapeutics: Company Snapshot
  • Table 8.12 Feel Therapeutics: Digital Biomarker Solutions Portfolio
  • Table 8.13 Feel Therapeutics: Recent Developments and Future Outlook
  • Table 8.14 AliveCor: Company Snapshot
  • Table 8.15 AliveCor: Digital Biomarker Solutions Portfolio
  • Table 8.16 AliveCor: Recent Developments and Future Outlook
  • Table 8.14 AliveCor: Company Snapshot
  • Table 8.15 AliveCor: Digital Biomarker Solutions Portfolio
  • Table 8.16 AliveCor: Recent Developments and Future Outlook
  • Table 8.17 BACtrack: Company Snapshot
  • Table 8.18 BACtrack: Digital Biomarker Solutions Portfolio
  • Table 8.19 Empatica: Company Snapshot
  • Table 8.20 Empatica: Digital Biomarker Solutions Portfolio
  • Table 8.21 Empatica: Recent Developments and Future Outlook
  • Table 8.22 icometrix: Company Snapshot
  • Table 8.23 icometrix: Digital Biomarker Solutions Portfolio
  • Table 8.24 icometrix: Recent Developments and Future Outlook
  • Table 8.25 Biogen: Company Snapshot
  • Table 8.26 Biogen: Digital Biomarker Solutions Portfolio
  • Table 8.27 Biogen: Recent Developments and Future Outlook
  • Table 8.28 Acculi Labs: Company Snapshot
  • Table 8.29 Acculi Labs: Digital Biomarker Solutions Portfolio
  • Table 8.30 IXICO: Company Snapshot
  • Table 8.31 IXICO: Digital Biomarker Solutions Portfolio
  • Table 8.32 Kinsa: Company Snapshot
  • Table 8.33 Kinsa: Digital Biomarker Solutions Portfolio
  • Table 8.34 Progentec Diagnostics: Company Snapshot
  • Table 8.35 Progentec Diagnostics: Digital Biomarker Solutions Portfolio
  • Table 8.36 Vocalis Health: Company Snapshot
  • Table 8.37 Vocalis Health: Digital Biomarker Solutions Portfolio
  • Table 8.38 Kontigo Care: Company Snapshot
  • Table 8.39 Kontigo Care: Digital Biomarker Solutions Portfolio
  • Table 8.40 Koneksa Health: Company Snapshot
  • Table 8.41 Koneksa Health: Digital Biomarker Solutions Portfolio
  • Table 8.42 ActiGraph: Company Snapshot
  • Table 8.43 ActiGraph: Digital Biomarker Solutions Portfolio
  • Table 8.44 BioSerenity: Company Snapshot
  • Table 8.45 BioSerenity: Digital Biomarker Solutions Portfolio
  • Table 8.46 ATCOR: Company Snapshot
  • Table 8.47 ATCOR: Digital Biomarker Solutions Portfolio
  • Table 8.48 iMediSync: Company Snapshot
  • Table 8.49 iMediSync: Digital Biomarker Solutions Portfolio
  • Table 11.1 Digital Biomarker Solutions: List of Global Events
  • Table 11.3 Global Events Analysis: Information on Name of Speakers and their Designations
  • Table 9.1 Digital Biomarker Solutions: List of Partnerships and Collaborations, Pre-2019-2024
  • Table 10.1 Digital Biomarker Solutions: List of Funding and Investments, Pre-2018-2024
  • Table 11.1 Digital Biomarker Solutions: List of Global Events
  • Table 11.2 Global Events Analysis: Information on Name of Speakers and their Designations
  • Table 12.1 Patent Analysis: Top CPC Sections
  • Table 12.2 Patent Analysis: Top CPC Symbols
  • Table 12.3 Patent Analysis: List of Top CPC Codes
  • Table 12.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 12.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 12.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
  • Table 23.1 Acculi Labs: Company Snapshot
  • Table 23.2 IXICO: Company Snapshot
  • Table 23.3 Tilak Healthcare: Company Snapshot
  • Table 23.4 Vocalis Health: Company Snapshot
  • Table 24.1 Digital Biomarker Solutions: Distribution by Type of Product
  • Table 24.2 Digital Biomarker Solutions: Distribution by Type of Digital Biomarker Solution
  • Table 24.3 Digital Biomarker Solutions: Distribution by Type of Biomarker
  • Table 24.4 Digital Biomarker Solutions: Distribution by Status of Development
  • Table 24.5 Digital Biomarker Solutions: Distribution by Type of Biomarker and Status of Development
  • Table 24.6 Digital Biomarker Solutions: Distribution by Purpose of Digital Biomarker Solution
  • Table 24.7 Digital Biomarker Solutions: Distribution by Target Therapeutic Area
  • Table 24.8 Digital Biomarker Solutions: Distribution by Type of Biomarker and Target Therapeutic Area
  • Table 24.9 Digital Biomarker Solutions: Distribution by Target Population
  • Table 24.10 Digital Biomarker Solutions: Distribution by End-user
  • Table 24.11 Digital Biomarker Solutions: Distribution by Availability of Clinical Validation
  • Table 24.12 Digital Biomarker Solutions: Distribution of Clinically Validated Solutions by Target Therapeutic Area
  • Table 24.13 Digital Biomarker Solutions: Distribution by Availability of AI Integration
  • Table 24.14 Digital Biomarker Solution Developers: Distribution by Year of Establishment
  • Table 24.15 Digital Biomarker Solution Developers: Distribution by Company Size
  • Table 24.16 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Region)
  • Table 24.17 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Country)
  • Table 24.18 Digital Biomarker Solution Developers: Distribution by Company Size and Location of Headquarters
  • Table 24.19 Most Active Players: Distribution by Number of Digital Biomarker Solutions Developed
  • Table 24.20 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2019 - 2024
  • Table 24.21 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 24.22 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 24.23 Partnerships and Collaborations: Distribution by Type of Biomarker
  • Table 24.24 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biomarker
  • Table 24.25 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 24.26 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Table 24.27 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 24.28 Most Active Players: Distribution by Number of Partnerships
  • Table 24.29 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Table 24.30 Partnerships and Collaborations: International and Local Deals
  • Table 24.31 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, Pre-2018-2024
  • Table 24.32 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, Pre-2018-2024
  • Table 24.33 Funding and Investment: Distribution by Type of Funding
  • Table 24.34 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 24.35 Funding and Investments: Distribution by Type of Biomarker
  • Table 24.36 Funding and Investments: Distribution by Therapeutic Area
  • Table 24.37 Leading Investors: Distribution by Number of Funding Instances
  • Table 24.38 Most Active Players: Distribution by Number of Funding Instances
  • Table 24.39 Most Active Players: Distribution by Amount Raised
  • Table 24.40 Funding and Investments: Distribution by Geography (Region)
  • Table 24.41 Funding and Investments: Distribution by Geography (Country)
  • Table 24.42 Global Events Analysis: Cumulative Year-wise Trend, H1 2021 - H1 2024
  • Table 24.43 Global Events Analysis: Distribution by Type of Event
  • Table 24.44 Global Events Analysis: Distribution by Year and Type of Event
  • Table 24.45 Global Events Analysis: Distribution by Event Platform
  • Table 24.46 Global Events Analysis: Distribution by Location of Event (Region)
  • Table 24.47 Global Events Analysis: Distribution by Location of Event (Country)
  • Table 24.48 Most Active Event Organizers: Distribution by Number of Events
  • Table 24.49 Most Active Players: Distribution by Number of Events
  • Table 24.50 Most Active Speakers: Distribution by Number of Events
  • Table 24.51 Distribution by Designation / Qualification of Speakers
  • Table 24.52 Patent Analysis: Distribution by Type of Patent
  • Table 24.53 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2018-2023
  • Table 24.54 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, 2019-2023
  • Table 24.55 Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2019-2023
  • Table 24.56 Patent Analysis: Distribution by Patent Jurisdiction (Region)
  • Table 24.57 Patent Analysis: Distribution by Patent Jurisdiction (Country)
  • Table 24.58 Patent Analysis: Distribution by Patent Publication Year and Type of Applicant
  • Table 24.59 Leading Players: Distribution by Number of Patents
  • Table 24.60 Leading Patent Assignees: Distribution by Number of Patents
  • Table 24.61 Patent Analysis: Distribution by Patent Age
  • Table 24.62 Digital Biomarker Solutions: Patent Valuation
  • Table 24.63 Global Digital Biomarker Solutions Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Table 24.64 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
  • Table 24.65 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
  • Table 24.66 Digital Biomarker Solutions Market for Software / Applications, Historical Trends (2018-2023) (USD Million)
  • Table 24.67 Digital Biomarker Solutions Market: Distribution by Type of Product, 2018, 2024 and 2035
  • Table 24.68 Digital Biomarker Solutions Market for Wearables, Historical Trends (2018-2023) (USD Million)
  • Table 24.69 Digital Biomarker Solutions Market for Software / Applications, Forecasted Estimates (2024-2035) (USD Million)
  • Table 24.70 Digital Biomarker Solutions Market for Sensors, Historical Trends (2018-2023) (USD Million)
  • Table 24.71 Digital Biomarker Solutions Market for Wearables, Forecasted Estimates (2024-2035) (USD Million)
  • Table 24.72 Digital Biomarker Solutions Market for Gaming Solutions, Historical Trends (2018-2023) (USD Million)
  • Table 24.73 Digital Biomarker Solutions Market for Gaming Solutions, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.74 Biomarker Solutions Market: Distribution by Purpose of Solution, 2018, 2024 and 2035
  • Table 24.75 Biomarker Solutions Market for Monitoring, Historical Trends (2018-2023) (USD Million)
  • Table 24.76 Digital Biomarker Solutions Market for Monitoring, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.77 Biomarker Solutions Market for Diagnosis, Historical Trends (2018-2023) (USD Million)
  • Table 24.78 Biomarker Solutions Market for Diagnosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.79 Digital Biomarker Solutions Market for Early Detection, Historical Trends (2018-2023) (USD Million)
  • Table 24.80 Digital Biomarker Solutions Market for Early Detection, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.81 Biomarker Solutions Market for Predictive Insights, Historical Trends (2018-2023) (USD Million)
  • Table 24.82 Digital Biomarker Solutions Market for Predictive Insights, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.83 Digital Biomarker Solutions Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
  • Table 24.84 Digital Biomarker Solutions Market for Physiological Biomarkers, Historical Trends (2018-2023) (USD Million)
  • Table 24.85 Digital Biomarker Solutions Market for Physiological Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.86 Digital Biomarker Solutions Market for Vocal Biomarkers, Historical Trends (2018-2023) (USD Million)
  • Table 24.87 Digital Biomarker Solutions Market for Vocal Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.88 Digital Biomarker Solutions Market for Cognitive Biomarkers, Historical Trends (2018-2023) (USD Million)
  • Table 24.89 Digital Biomarker Solutions Market for Cognitive Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.90 Digital Biomarker Solutions Market for Idiosyncratic Biomarkers, Historical Trends (2018-2023) (USD Million)
  • Table 24.91 Digital Biomarker Solutions Market for Idiosyncratic Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.92 Digital Biomarker Solutions Market for Other Biomarkers, Historical Trends (2018-2023) (USD Million)
  • Table 24.93 Digital Biomarker Solutions Market for Other Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.94 Digital Biomarker Solutions Market: Distribution by Therapeutic Area, 2018, 2024 and 2035 (USD Million)
  • Table 24.95 Digital Biomarker Solutions Market for Neurological Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.96 Digital Biomarker Solutions Market for Neurological Disorders, Forecasted Estimates (2024-2035) Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.97 Digital Biomarker Solutions Market for Mental Health Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.98 Digital Biomarker Solutions Market for Mental Health Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.99 Digital Biomarker Solutions Market for Cardiovascular Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.100 Digital Biomarker Solutions Market for Cardiovascular Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.101 Digital Biomarker Solutions Market for Infectious Diseases, Historical Trends (2018-2023) (USD Million)
  • Table 24.102 Digital Biomarker Solutions Market for Infectious Diseases, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.103 Digital Biomarker Solutions Market for Respiratory Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.104 Digital Biomarker Solutions Market for Respiratory Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.105 Digital Biomarker Solutions Market for Autoimmune Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.106 Digital Biomarker Solutions Market for Autoimmune Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.107 Digital Biomarker Solutions Market for Substance Abuse Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.108 Digital Biomarker Solutions Market for Substance Abuse Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.109 Digital Biomarker Solutions Market for Other Disorders, Historical Trends (2018-2023) (USD Million)
  • Table 24.110 Digital Biomarker Solutions Market for Other Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.111 Digital Biomarker Solutions Market: Distribution by Business Model, 2018, 2024 and 2035
  • Table 24.112 Digital Biomarker Solutions Market for B2B Model, Historical Trends (2018-2023) (USD Million)
  • Table 24.113 Digital Biomarker Solutions Market for B2B Model, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.114 Digital Biomarker Solutions Market for B2C Model, Historical Trends (2018-2023) (USD Million)
  • Table 24.115 Digital Biomarker Solutions Market for B2C Model, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.116 Digital Biomarker Solutions Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
  • Table 24.117 Digital Biomarker Solutions Market in North America, Historical Trends (2018-2023) (USD Million)
  • Table 24.118 Digital Biomarker Solutions Market in North America, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.119 Digital Biomarker Solutions Market in Europe, Historical Trends (2018-2023) (USD Million)
  • Table 24.120 Digital Biomarker Solutions Market in Europe, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.121 Digital Biomarker Solutions Market in Asia-Pacific, Historical Trends (2018-2023) (USD Million)
  • Table 24.122 Digital Biomarker Solutions Market in Asia-Pacific, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.123 Digital Biomarker Solutions Market in Middle East and North Africa, Historical Trends (2018-2023) (USD Million)
  • Table 24.124 Digital Biomarker Solutions Market in Middle East and North Africa, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.125 Digital Biomarker Solutions Market in Rest of the World, Historical Trends (2018-2023) (USD Million)
  • Table 24.126 Digital Biomarker Solutions Market in Rest of the World, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentation
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1 Executive Summary: Digital Biomarker Solutions Market Landscape
  • Figure 4.2 Executive Summary: Digital Biomarker Solution Developer Landscape
  • Figure 4.3 Executive Summary: Partnerships and Collaborations
  • Figure 4.4 Executive Summary: Funding and Investments
  • Figure 4.5 Executive Summary: Global Events Analysis
  • Figure 4.6 Executive Summary: Patent Analysis
  • Figure 4.7 Executive Summary: Digital Biomarker Solutions Market Forecast and Opportunity Analysis
  • Figure 5.1 Types of Digital Biomarkers
  • Figure 5.2 Types of Biomarkers / Signals Captured by Digital Biomarker Solutions
  • Figure 5.3 Emerging Focus Areas: Google News
  • Figure 6.1 Digital Biomarker Solutions: Distribution by Type of Product
  • Figure 6.2 Digital Biomarker Solutions: Distribution by Type of Digital Biomarker Solution
  • Figure 6.3 Digital Biomarker Solutions: Distribution by Type of Biomarker
  • Figure 6.4 Digital Biomarker Solutions: Distribution by Status of Development
  • Figure 6.5 Digital Biomarker Solutions: Distribution by Type of Biomarker and Status of Development
  • Figure 6.6 Digital Biomarker Solutions: Distribution by Purpose of Digital Biomarker Solution
  • Figure 6.7 Digital Biomarker Solutions: Distribution by Target Therapeutic Area
  • Figure 6.8 Digital Biomarker Solutions: Distribution by Type of Biomarker and Target Therapeutic Area
  • Figure 6.9 Digital Biomarker Solutions: Distribution by Target Population
  • Figure 6.10 Digital Biomarker Solutions: Distribution by End-user
  • Figure 6.11 Digital Biomarker Solutions: Distribution by Availability of Clinical Validation
  • Figure 6.12 Digital Biomarker Solutions: Distribution of Clinically Validated Solutions by Target Therapeutic Area
  • Figure 6.13 Digital Biomarker Solutions: Distribution by Availability of AI Integration
  • Figure 6.14 Digital Biomarker Solution Developers: Distribution by Year of Establishment
  • Figure 6.15 Digital Biomarker Solution Developers: Distribution by Company Size
  • Figure 6.16 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Region)
  • Figure 6.17 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Country)
  • Figure 6.18 Digital Biomarker Solution Developers: Distribution by Company Size and Location of Headquarters
  • Figure 6.19 Most Active Players: Distribution by Number of Digital Biomarker Solutions Developed
  • Figure 7.1 Product Competitiveness Analysis: Digital Biomarker Solutions Developed by Players based in North America
  • Figure 7.2 Product Competitiveness Analysis: Digital Biomarker Solutions Developed by Players based in Europe
  • Figure 7.3 Product Competitiveness Analysis: Digital Biomarker Solutions Developed by Players based in Asia-Pacific and Rest of the World
  • Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2019 - 2024
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 9.4 Partnerships and Collaborations: Distribution by Type of Biomarker
  • Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biomarker
  • Figure 9.6 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Figure 9.8 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 9.9 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 9.11 Partnerships and Collaborations: International and Local Deals
  • Figure 10.1 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, Pre-2018-2024
  • Figure 10.2 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, Pre-2018-2024
  • Figure 10.3 Funding and Investment: Distribution by Type of Funding
  • Figure 10.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 10.5 Funding and Investments: Distribution by Type of Biomarker
  • Figure 10.6 Funding and Investments: Distribution by Therapeutic Area
  • Figure 10.7 Leading Investors: Distribution by Number of Funding Instances
  • Figure 10.8 Most Active Players: Distribution by Number of Funding Instances
  • Figure 10.9 Most Active Players: Distribution by Amount Raised
  • Figure 10.10 Funding and Investments: Distribution by Geography (Region)
  • Figure 10.11 Funding and Investments: Distribution by Geography (Country)
  • Figure 11.1 Global Events Analysis: Cumulative Year-wise Trend, H1 2021 - H1 2024
  • Figure 11.2 Global Events Analysis: Distribution by Type of Event
  • Figure 11.3 Global Events Analysis: Distribution by Year and Type of Event
  • Figure 11.4 Global Events Analysis: Distribution by Event Platform
  • Figure 11.5 Global Events Analysis: Distribution by Location of Event (Region)
  • Figure 11.6 Global Events Analysis: Distribution by Location of Event (Country)
  • Figure 11.7 Word Cloud Analysis: Key Focus Areas
  • Figure 11.8 Most Active Event Organizers: Distribution by Number of Events
  • Figure 11.9 Most Active Players: Distribution by Number of Events
  • Figure 11.10 Most Active Speakers: Distribution by Number of Events
  • Figure 11.11 Distribution by Designation / Qualification of Speakers
  • Figure 12.1 Patent Analysis: Distribution by Type of Patent
  • Figure 12.2 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2018-2023
  • Figure 12.3 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, 2019-2023
  • Figure 12.4 Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2019-2023
  • Figure 12.5 Patent Analysis: Distribution by Patent Jurisdiction (Region)
  • Figure 12.6 Patent Analysis: Distribution by Patent Jurisdiction (Country)
  • Figure 12.7 Patent Analysis: Distribution by CPC Symbols
  • Figure 12.8 Patent Analysis: Distribution by Patent Publication Year and Type of Applicant
  • Figure 12.9 Leading Players: Distribution by Number of Patents
  • Figure 12.10 Leading Patent Assignees: Distribution by Number of Patents
  • Figure 12.11 Patent Benchmarking: Distribution of Patent Characteristics (CPC Codes) by Leading Players
  • Figure 12.12 Patent Benchmarking: Distribution of Leading Players by Patent Characteristics (Top CPC Codes)
  • Figure 12.13 Patent Analysis: Distribution by Patent Age
  • Figure 12.14 Digital Biomarker Solutions: Patent Valuation
  • Figure 13.1 Big Pharma Initiatives Related to Digital Biomarker Solutions: Distribution by Type of Initiative
  • Figure 13.2 Big Pharma Initiatives Related to Digital Biomarker Solutions: Heat Map Analysis
  • Figure 13.7 Spider Web Analysis: AbbVie
  • Figure 13.8 Spider Web Analysis: Amgen
  • Figure 13.9 Spider Web Analysis: AstraZeneca
  • Figure 13.10 Spider Web Analysis: Bayer
  • Figure 13.11 Spider Web Analysis: Bristol Myers Squibb
  • Figure 13.12 Spider Web Analysis: Eli Lilly
  • Figure 13.13 Spider Web Analysis: GlaxoSmithKline
  • Figure 13.14 Spider Web Analysis: Johnson & Johnson
  • Figure 13.15 Spider Web Analysis: Merck
  • Figure 13.16 Spider Web Analysis: Novartis
  • Figure 13.17 Spider Web Analysis: Pfizer
  • Figure 13.18 Spider Web Analysis: Roche
  • Figure 13.19 Spider Web Analysis: Sanofi
  • Figure 13.20 . Spider Web Analysis: Takeda Pharmaceuticals
  • Figure 15.1 Global Digital Biomarker Solutions Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 15.2 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
  • Figure 15.3 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
  • Figure 16.1 Digital Biomarker Solutions Market: Distribution by Type of Product, 2018, 2024 and 2035
  • Figure 16.2 Digital Biomarker Solutions Market for Software / Applications: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 16.3 Digital Biomarker Solutions Market for Wearables: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 16.4 Digital Biomarker Solutions Market for Sensors: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 16.5 Digital Biomarker Solutions Market for Gaming Solutions: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 17.1 Digital Biomarker Solutions Market: Distribution by Purpose of Solution, 2018, 2024 and 2035
  • Figure 17.2 Digital Biomarker Solutions Market for Monitoring: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 17.3 Digital Biomarker Solutions Market for Diagnosis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 17.4 Digital Biomarker Solutions Market for Early Detection: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 17.5 Digital Biomarker Solutions Market for Predictive Insights: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 18.1 Digital Biomarker Solutions Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
  • Figure 18.2 Digital Biomarker Solutions Market for Physiological Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 18.3 Digital Biomarker Solutions Market for Vocal Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 18.4 Digital Biomarker Solutions Market for Cognitive Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 18.5 Digital Biomarker Solutions Market for Idiosyncratic Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 18.6 Digital Biomarker Solutions Market for Other Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.1 Digital Biomarker Solutions Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
  • Figure 19.2 Digital Biomarker Solutions Market for Neurological Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.3 Digital Biomarker Solutions Market for Mental Health Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.4 Digital Biomarker Solutions Market for Cardiovascular Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.5 Digital Biomarker Solutions Market for Infectious Diseases: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.6 Digital Biomarker Solutions Market for Respiratory Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.7 Digital Biomarker Solutions Market for Autoimmune Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.8 Digital Biomarker Solutions Market for Substance Abuse Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 19.9 Digital Biomarker Solutions Market for Other Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 20.1 Digital Biomarker Solutions Market: Distribution by Business Model, 2018, 2024 and 2035
  • Figure 20.2 Digital Biomarker Solutions Market for B2B Model: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 20.3 Digital Biomarker Solutions Market for B2C Model: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 21.1 Digital Biomarker Solutions Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
  • Figure 21.2 Digital Biomarker Solutions Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 21.3 Digital Biomarker Solutions Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 21.4 Digital Biomarker Solutions Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 21.5 Digital Biomarker Solutions Market in Middle East and North Africa: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 21.6 Digital Biomarker Solutions Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 22.1 Concluding Remarks: Digital Biomarker Solutions Market Landscape
  • Figure 22.2 Concluding Remarks: Digital Biomarker Solution Developers Landscape
  • Figure 22.3 Concluding Remarks: Partnerships and Collaborations
  • Figure 22.4 Concluding Remarks: Funding and Investment
  • Figure 22.5 Concluding Remarks: Global Events Analysis
  • Figure 22.6 Concluding Remarks: Patent Analysis
  • Figure 22.7 Concluding Remarks: Market Sizing and Opportunity Analysis (I/II)
  • Figure 22.8 Concluding Remarks: Market Sizing and Opportunity Analysis (II/II)